The results, consistent with the lnc-ZEB2-19 overexpression, showed that the knockdown of TRA2A and RSPH14 could distinctly inhibit proliferation, migration, invasion, stemness, and resistance to lenvatinib of HCC cell lines. The gene discussed is ZEB2; the disease is hepatocellular carcinoma.